Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions

Autor: Annika Anderson, William Rowles, Shane Poole, Ayushi Balan, Carolyn Bevan, Rachel Brandstadter, Andrea I. Ciplea, Joanna Cooper, Michelle Fabian, Thomas W. Hale, Dina Jacobs, Mihir Kakara, Kristen M. Krysko, Erin E. Longbrake, Jacqueline Marcus, Pavle Repovic, Claire S. Riley, Andrew R. Romeo, Alice Rutatangwa, Timothy West, Kerstin Hellwig, Sara C. LaHue, Riley Bove

Publikováno v: Annals of Clinical and Translational Neurology, Vol 10, Iss 11, Pp 2053-2064 (2023)

Abstract Objective Postpartum, patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) have increased risk for disease activity. Anti‐CD20 IgG1 monoclonal antibodies (mAb) are increasingly used as disease‐modifyin

Externí odkaz: https://doaj.org/article/5711916b3a49420fb8c37e9ca7013cec

Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis

Autor: Rebecca I. Spain, Andrea Hildebrand, Carin S. Waslo, William D. Rooney, Joshua Emmons, Daniel L. Schwartz, Mark S. Freedman, M. Mateo Paz Soldan, Pavle Repovic, Andrew J. Solomon, John Rinker, Mitchell Wallin, Jodie K. Haselkorn, Olaf Stuve, Robert H. Gross, Aaron P. Turner

Publikováno v: Frontiers in Neurology, Vol 14 (2023)

BackgroundCognitive dysfunction and brain atrophy are both common in progressive multiple sclerosis (MS) but are seldom examined comprehensively in clinical trials. Antioxidant treatment may affect the neurodegeneration characteristic of progressive

Externí odkaz: https://doaj.org/article/f92e810a84084b538afa13a6598b19e5

Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial

Autor: Robert A. Bermel, Emmanuelle Waubant, Gabriel Pardo, Ann Bass, Pavle Repovic, Scott Newsome, John W. Lindsey, Deidre Kile, Ashish Pradhan, Bruno Musch, Aram Zabeti

Publikováno v: Annals of Clinical and Translational Neurology, Vol 8, Iss 3, Pp 711-715 (2021)

Abstract The CHORDS trial evaluated ocrelizumab (OCR) in patients with relapsing‐remitting multiple sclerosis who had a suboptimal response to previous disease‐modifying treatment. The objective of the present study was to assess the safety of sh

Externí odkaz: https://doaj.org/article/619def2a12d34255b912713dba9a29f1

Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis.

Autor: Koch MW; Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada., Repovic P; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, USA., Mostert J; Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands., Bowen JD; Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, USA., Comtois J; Department of Medicine, Neurology service, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.; Département de neurosciences, Faculté de médecine, Université de Montréal, Montreal, Quebec, Canada., Strijbis E; Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Uitdehaag B; Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Cutter G; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Publikováno v: European journal of neurology [Eur J Neurol] 2023 Sep; Vol. 30 (9), pp. 2761-2768. Date of Electronic Publication: 2023 Jun 20.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.